Education
About Us
Working with TipRanks
Follow Us
Biogen Inc. (BIIB)
:BIIB
BIIB Stock Chart & Stats
$156.74
-$1.36(-0.89%)
At close: 4:00 PM EST
$156.74
-$1.36(-0.89%)
Day’s Range― - ―
52-Week Range$110.04 - $175.86
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.73M
Market Cap
$22.51B
Enterprise Value$23.24B
Total Cash (Recent Filing)$3.96B
Total Debt (Recent Filing)$6.59B
Price to Earnings (P/E)14.3
Beta0.65
Next Earnings
Jan 29, 2026EPS Estimate
1.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.81
Shares Outstanding146,702,270
10 Day Avg. Volume1,892,162
30 Day Avg. Volume1,733,986
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.33
Price to Sales (P/S)2.30
P/FCF Ratio8.86
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda6.65
Forecast
1Y Price Target
$181.71Price Target Upside15.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EarningsQ3 results were strong with a significant beat driven by continued resilience in the MS segment.
Pipeline OpportunitiesBiogen is entering a catalyst-dense period with multiple late-stage opportunities across Alzheimer’s, lupus, SMA, and Parkinson’s.
Product LaunchesManagement seems particularly excited about sales from product launches as Leqembi, Skyclarys, Zurzuvae, and Qalsody together delivered 67% year-over-year growth.
Bears Say
Competitive EnvironmentThe broader competitive environment looks increasingly challenging with LL Y's Kisunla catching up to Leqembi's lead.
Pipeline DevelopmentThe company's pipeline is expected to remain underdeveloped following recent program cost cuts.
Sales PerformanceLeqembi sales of $121M underwhelmed, coming in 6% below consensus.
Biogen News
BIIB FAQ
What was Biogen Inc.’s price range in the past 12 months?
Biogen Inc. lowest stock price was $110.03 and its highest was $175.86 in the past 12 months.
What is Biogen Inc.’s market cap?
Biogen Inc.’s market cap is $22.51B.
When is Biogen Inc.’s upcoming earnings report date?
Biogen Inc.’s upcoming earnings report date is Jan 29, 2026 which is in 82 days.
How were Biogen Inc.’s earnings last quarter?
Biogen Inc. released its earnings results on Oct 30, 2025. The company reported $4.81 earnings per share for the quarter, beating the consensus estimate of $3.882 by $0.928.
Is Biogen Inc. overvalued?
According to Wall Street analysts Biogen Inc.’s price is currently Undervalued.
Does Biogen Inc. pay dividends?
Biogen Inc. does not currently pay dividends.
What is Biogen Inc.’s EPS estimate?
Biogen Inc.’s EPS estimate is 1.87.
How many shares outstanding does Biogen Inc. have?
Biogen Inc. has 146,702,270 shares outstanding.
What happened to Biogen Inc.’s price movement after its last earnings report?
Biogen Inc. reported an EPS of $4.81 in its last earnings report, beating expectations of $3.882. Following the earnings report the stock price went up 1.184%.
Which hedge fund is a major shareholder of Biogen Inc.?
Currently, no hedge funds are holding shares in BIIB
Biogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$181.71 (15.93% Upside)
$181.71 (15.93% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 124.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $69.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.12%
12-Months-Change
Fundamentals
Return on Equity
9.31%
Trailing 12-Months
Asset Growth
3.16%
Trailing 12-Months
Company Description
Biogen Inc.
Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen focuses on areas such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, offering a range of products including well-known medications like Tecfidera, Avonex, and Spinraza. The company's commitment to research and development drives its pipeline of potential treatments, positioning it as a leader in the biotechnology sector.
BIIB Company Deck
BIIB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biogen's earnings call reflected a strong performance in new product launches and pipeline progress, with significant revenue growth in key segments offsetting some challenges, particularly in Europe and China. The financial results and strategic focus on pipeline expansion suggest a positive outlook.View all BIIB earnings summariesBIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
6.74% Contract manufacturing, royalty and other revenue
0.62% Alzheimer's collaboration revenue
BIIB Stock 12 Month Forecast
Average Price Target
$181.71
▲(15.93% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
31.68% Mutual Funds
0.26% Other Institutional Investors
36.12% Public Companies and Individual Investors